Detection Windows for Ketamine and Cocaine

Ketamine – Biological Specimen Detection

Urine testing detects ketamine in most individuals within 24–72 hours after a single use. 1
Blood testing can identify ketamine for approximately 24 hours after ingestion, and is most informative for 2–12 hours post‑use when correlating concentrations with impairment. 2
Hair analysis (first 3 cm) provides a detection window of up to 90 days, but cannot reveal use that occurred within the previous 7–10 days because of the time needed for drug incorporation into the hair matrix. 2
Saliva testing identifies recent ketamine exposure for 24–48 hours after use and offers a less invasive alternative to blood, capturing drug that may still be undetectable in urine. 2

Urine testing reveals cocaine metabolites in the typical user for 24–48 hours after use. 3
The primary metabolite, benzoylecgonine, has a urinary half‑life of 6–8 hours; the mean time to a first negative urine specimen after intranasal use is 43.6 ± 17.1 hours (range 16–66 hours). 3
In chronic heavy users (up to 10 g/day), benzoylecgonine may remain detectable for up to 22 days after the last dose. 3
Standard immunoassays employ a 300 ng/mL cut‑off for benzoylecgonine detection. 3
Blood testing is useful for acute presentations, detecting cocaine primarily within 2–12 hours after use. 3
Saliva testing identifies cocaine use for 24–48 hours post‑exposure. 2
Sweat patches can capture cocaine and its metabolites (benzoylecgonine, ecgonine methyl ester) from 48 hours before patch application and continuously throughout a 3–7 day wear period, though results may be affected by environmental contamination. 4

Because both ketamine and cocaine have short detection windows, toxicology screening should be performed as soon as possible when drug‑facilitated scenarios are suspected. 1
In time‑sensitive situations, specimen collection may need to precede a full history and physical examination to avoid missing the detection window. 1
Standard drug‑screening panels often omit ketamine and specific cocaine metabolites; clinicians must verify which substances their laboratory can detect and ensure proper specimen collection. 1
Individual variability in metabolism and excretion can influence quantitative test results, necessitating cautious interpretation. 3
Persistent cocaine use after initial presentation is associated with higher rates of recurrent cardiac events and increased mortality. 3

Cocaine and its metabolite benzoylecgonine are detectable in blood for approximately 2–12 hours after use, making blood analysis most useful for acute presentations when recent use and level of impairment need to be correlated. 5
Blood sampling is invasive, relatively costly, and requires specially trained personnel to obtain and process specimens. 5

Cocaine can be identified in saliva for 24–48 hours after use; this non‑invasive matrix captures recent drug exposure that may not yet appear in urine. 5
Point‑of‑care saliva tests are commercially available, facilitating rapid bedside screening. 5
Factors such as smoking or methods used to stimulate saliva production can influence test results and should be considered when interpreting findings. 5

Transdermal sweat patches detect cocaine use that occurred within 48 hours before patch application and continue to monitor ongoing use throughout the 3–7‑day wear period. 5
Environmental contamination of the patch can produce false‑positive results; proper handling and storage are essential. 5
Separate sweat swabs (swipes) are capable of identifying cocaine use within the preceding 24 hours. 5

When drug‑facilitated assault or intoxication is suspected, specimens should be collected immediately, ideally before completing the history and physical examination, to avoid missing the narrow detection window. 6
Coordination with sexual‑assault response teams and law‑enforcement agencies is recommended to ensure proper chain of custody and legal admissibility of the specimens. 6

Routine drug‑screening panels often omit specific cocaine metabolites; clinicians must verify which substances are included in their laboratory’s assay panel. 6
Flunitrazepam and related “date‑rape” drugs are not identified by standard benzodiazepine screens and require dedicated testing. 6
Documentation of the chain of custody for any specimen intended for legal proceedings is mandatory to preserve evidentiary integrity. 6
The presence of voluntary substance use proximate to an event (e.g., sexual assault) does not diminish the standard of care required for clinical evaluation and management. 6
In studies of suspected drug‑facilitated sexual assault, cocaine was detected in approximately 19 %–32 % of cases, underscoring its relevance in forensic investigations. 6